ArticleHistochemistry and cell biology2025
EP300 genomic redistribution following E-cadherin inhibition in MCF7 cancer cells: evidence for early epigenetic reprogramming.
Article in Histochemistry and cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
E-cadherin is a key determinant of epithelial tissue architecture, and its inhibition has been linked to transcriptional reprogramming and cellular plasticity in epithelial cancers. However, the chromatin-level mechanisms driving these changes remain incompletely understood. EP300, a histone acetyltransferase and transcriptional coactivator, has been implicated in mediating epigenetic responses to cell-cell adhesion loss. We examined the genome-wide chromatin binding profile of EP300 in MCF7 breast cancer cells following functional inhibition of E-cadherin using a neutralizing antibody. Chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-seq) revealed 4128 EP300-enriched regions in control cells and 2943 in treated cells, with only 12 sites shared between conditions, indicating widespread redistribution. These changes localized to gene loci associated with epithelial identity (e.g., CDH1, CD46) and were replaced by increased occupancy at mesenchymal (CDH2, LOX) and pluripotency-associated loci (SEMA3E, MET). Differential binding was validated by chromatin immunoprecipitation coupled with quantitative polymerase chain reaction (ChIP-qPCR). Notably, EP300 protein levels remained unchanged, suggesting a redistribution rather than expression-level regulation. Our findings suggest that E-cadherin inhibition is associated with early changes in EP300 chromatin localization, particularly at loci linked to epithelial-mesenchymal transition (EMT) and pluripotency. These changes may reflect an early chromatin-level response to altered cell adhesion, warranting further functional investigation.
Indexed as
Identifiers
41081952What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.